KNIGHT, Andrea and Martin PISKÁČEK. Cryptic inhibitory regions nearby activation domains. Biochimie. ISSY-LES-MOULINEAUX: Elsevier, 2022, vol. 200, September 2022, p. 19-26. ISSN 0300-9084. Available from: https://dx.doi.org/10.1016/j.biochi.2022.05.004.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cryptic inhibitory regions nearby activation domains
Authors KNIGHT, Andrea (203 Czech Republic, belonging to the institution) and Martin PISKÁČEK (40 Austria, guarantor, belonging to the institution).
Edition Biochimie, ISSY-LES-MOULINEAUX, Elsevier, 2022, 0300-9084.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.900
RIV identification code RIV/00216224:14110/22:00129669
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.biochi.2022.05.004
UT WoS 000806357600003
Keywords in English Transcription; Gal4; MED15; 9aaTAD
Tags 14110518, rivok
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/7/2022 09:20.
Abstract
Previously, the Nine amino acid TransActivation Domain (9aaTAD) was identified in the Gal4 region 862–870 (DDVYNYLFD). Here, we identified 9aaTADs in the distal Gal4 orthologs by our prediction algorithm and found their conservation in the family. The 9aaTAD function as strong activators was demonstrated. We identified adjacent Gal4 region 871–811 (DEDTPPNPKKE) as a natural 9aaTAD inhibitory domain located at the extreme Gal4 terminus. Moreover, we identified conserved Gal4 region 172–185 (FDWSEEDDMSDGLP), which was capable to reverse the 9aaTAD inhibition. In conclusion, our results uncover the existence of the cryptic inhibitory domains, which need to be carefully implemented in all functional studies with transcription factors to avoid incorrect conclusions.
Links
NV19-05-00410, research and development projectName: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme
Investor: Ministry of Health of the CR
PrintDisplayed: 30/7/2024 03:24